Model included BMI, first-degree relative family history of CRC, other family history of CRC, tobacco use as factors.

The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

Researchers reviewed the impact of prehabilitation on several surgery outcomes measures in patients with colorectal cancer.

Discontinuing tyrosine kinase inhibitor maintenance after extended complete molecular response should only be attempted as part of a clinical trial, the researchers say.

Minimal residual disease negativity was achieved at a significantly higher rate with venetoclax-based therapies, supporting its role in CLL.

The dose of paclitaxel used in the new approach was 16-fold lower than that typically used in free paclitaxel, but with similar efficacy.

A rare case has been reported of diffuse large B-cell lymphoma (DLBCL) presenting initially as cold agglutinin disease (CAD). The report, published in the Kaohsiung Journal of Medical Sciences, ...

Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.

It is imperative to align strategies that can prevent ovarian cancer while also strengthening support for patients, caregivers, and health systems that are confronted by it,” the researchers wrote.

Rebounds seen in breast cancer and colonoscopy screening, while reported cervical cancer screening in 2023 remained below 2019 estimates.

Researchers sought to determine whether using HRD sources for HSCT would be effective for pediatric patients with hematologic cancers compared with UCB sources.

According to investigators, there is no validated PSA-based endpoint to compare oncologic outcomes after radical prostatectomy and radiation therapy for localized prostate cancer.